Literature DB >> 31740238

Lipoprotein(a) levels are associated with coronary severity but not with outcomes in Chinese patients underwent percutaneous coronary intervention.

Na Xu1, Xiao-Fang Tang1, Yi Yao1, Si-da Jia1, Yue Liu1, Xue-Yan Zhao1, Jue Chen1, Zhan Gao1, Yue-Jin Yang1, Run-Lin Gao1, Bo Xu1, Jin-Qing Yuan2.   

Abstract

BACKGROUND AND AIMS: The association between lipoprotein(a) [Lp(a)] levels and the risk of cardiovascular disease is of great interest but still controversial. This study sought to investigate the impact of Lp(a) on coronary severity and long-term outcomes of patients who undergo percutaneous coronary intervention (PCI). METHODS AND
RESULTS: A total of 6714 consecutive patients who received PCI were enrolled to analyze the association between Lp(a) and coronary severity and major adverse cardiovascular and cerebrovascular events (MACCE). Patients were divided into tertiles according to Lp(a) levels on admission. Coronary severity was evaluated by SYNTAX scoring system. The MACCE included recurrent myocardial infarction, unplanned target vessel revascularization, stent thrombosis, ischemic stroke and all-cause mortality. Significantly, Lp(a) levels were positively associated with coronary severity (p < 0.001). Multivariate logistic regression analyses showed Lp(a) was an independent predictor of intermediate to high SYNTAX score. During an average of 874 days follow-up, 755 patients presented with MACCE (11.25%) were reported. The incidence rates of MACCE, all-cause mortality, cardiac death, target vessel revascularization, recurrent myocardial infarction, stent thrombosis, stroke and bleeding were not statistically different among the Lp(a) tertile groups. Furthermore, both Kaplan-Meier and Cox regression analyses found no relationship between Lp(a) and cardiovascular outcomes (p > 0.05).
CONCLUSION: Lp(a) is an independent predictor of the prevalence of more complex coronary artery lesions (SYNTAX score ≥ 23) in patients with PCI. In addition, our study has shown that Lp(a) has no relationship with long-term cardiovascular outcomes in Chinese patients with PCI.
Copyright © 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Major adverse cardiovascular and cerebrovascular events; Percutaneous coronary intervention; SYNTAX; lipoprotein(a)

Year:  2019        PMID: 31740238     DOI: 10.1016/j.numecd.2019.09.020

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  4 in total

1.  The Association of Syntax Score with Levels of Lipoprotein(a) and Inflammatory Biomarkers in Patients with Stable Coronary Artery Disease and Different Low-Density Lipoprotein Cholesterol Levels.

Authors:  Weifeng Xu; Haiwang Guan; Da Gao; Zicheng Wang; Yanna Ba; Hao Yang; Wenjun Shen; Jiangfang Lian; Jianqing Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-12       Impact factor: 3.168

2.  Elevated lipoprotein(a) levels as an independent predictor of long-term recurrent events in patients with acute coronary syndrome: an observational, retrospective cohort study.

Authors:  Si-Qi Yang; Han-Xiong Liu; Xiu-Qiong Yu; Lin Tong; Xu Chen; Ling-Yao Qi; Cai-Yan Cui; Lian-Chao Cheng; Lin Cai
Journal:  Coron Artery Dis       Date:  2022-02-15       Impact factor: 1.717

3.  Elevated lipoprotein(a) and genetic polymorphisms in the LPA gene may predict cardiovascular events.

Authors:  Jun-Xu Gu; Juan Huang; Shan-Shan Li; Li-Hua Zhou; Ming Yang; Yang Li; Ai-Min Zhang; Yue Yin; Na Zhang; Mei Jia; Ming Su
Journal:  Sci Rep       Date:  2022-03-04       Impact factor: 4.379

4.  Association Between Lipoprotein(a) and Peri-procedural Myocardial Infarction in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention.

Authors:  Yupeng Liu; Wenyao Wang; Jingjing Song; Kuo Zhang; Bo Xu; Ping Li; Chunli Shao; Min Yang; Jing Chen; Yi-Da Tang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-03       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.